Balloon Valvuloplasty Devices Market Size, Share, and COVID-19 Impact Analysis, By Type (Aortic Valvuloplasty, Pulmonary Valvuloplasty, and Others), By Age Group (Pediatric and Adults), and By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global balloon valvuloplasty devices market size was valued at USD 2.5 billion in 2025. The market is projected to grow from USD 2.61 billion in 2026 to USD 3.61 billion by 2034, exhibiting a CAGR of 4.16% during the forecast period.

Balloon valvuloplasty devices are used to treat stenosis, the narrowing of a heart valve opening. The minimally invasive procedure used to open contracted heart valves is called balloon valvuloplasty. The procedure uses a catheter with a small deflated balloon at its tip. The balloon is inflated to open the valve and relieve the obstruction. Balloon valvuloplasty improves the blood flow and treats symptoms of cardiovascular devices.

The major factors driving the growth of the balloon valvuloplasty device market include the rapidly aging population and the increasing global prevalence rate of aortic valve stenosis.

• According to data published in the Journal of the European Society of Cardiology in February 2020, aortic stenosis is the second most common valvular lesion in the U.S.  It is present in about 5% of the population above age 65. Its prevalence increases with age.

Improving reimbursement guidelines for surgical procedures, increasing hospital investments in surgical devices, and rising R&D activities leading to technological advancements are additional factors propelling the market demand. Furthermore, a rising inclination toward minimally invasive procedures is projected to provide lucrative growth opportunities for market players. Minimally invasive procedures offer various advantages, including faster recovery, lower surgical complications, effective management of post-surgical pain, and shorter hospital stays, thereby influencing the market landscape.

However, balloon valvuloplasty procedures are expensive compared to traditional open-heart surgery. The cost of these procedures varies depending upon several factors, such as the type of device used, the patient’s insurance coverage, and the surgeon's experience. The high product cost may hamper the balloon valvuloplasty devices market growth to a certain extent.

Impact of COVID-19 on the Balloon Valvuloplasty Devices Market

The outbreak of the COVID-19 pandemic had a negative impact on the balloon valvuloplasty device market in 2020. The delay in diagnosis, treatments, and surgical procedures was observed in patients with various chronic and lifestyle-related diseases due to the lockdown restrictions imposed by government bodies. According to data published by the National Institutes of Health (NIH) in July 2021, a decline of 52.7% was observed in adult cardiac surgery procedures and 65.5% for elective procedures in the U.S.  

Considering an instance, Becton, Dickinson and Company, a major balloon valvuloplasty device manufacturer, witnessed a decline of 1% in their total revenues in 2020 compared to 2019. The decline was mainly attributed to the postponements or cancellations of elective surgeries, disruptions in the supply chain, and bio-manufacturing changes. However, in 2021, the market stabilized due to the lifting of restrictions imposed by the government and the resumption of surgical procedures.

Segmentation

Key Insights

The report covers the following key insights:

• Epidemiology of Heart Valve Diseases, By Key Countries
• Reimbursement Scenario for Key Countries
• Key Industry Developments - Mergers, Acquisitions, and Partnerships
• Impact of COVID-19 on the Market

Analysis By Type

In 2022, the aortic valvuloplasty segment accounted for the highest market share. The segment growth was attributed to the new product launches associated with the treatment of stenosis and various strategic initiatives undertaken by key players to sell and market their balloon aortic valvuloplasty products.

• For instance, in March 2021, Keystone Heart, Ltd., a medical device manufacturer, announced an exclusive distribution agreement with InterValve Medical, Inc. to sell and market their balloon aortic valvuloplasty products in the U.S.

The adoption of such strategic initiatives by companies is projected to expand the balloon valvuloplasty devices market size.

Moreover, the pulmonary valvuloplasty segment is estimated to hold the second-highest market share over the forecast period, 2023-2030. The segmental expansion is driven by the increasing prevalence of heart-related conditions, particularly in the elderly population. Further, increasing investments in research and development activities by manufacturers to introduce innovative products are projected to drive product adoption in the near future.

Regional Analysis

To gain extensive insights into the market, Download for Customization

North America accounted for the highest revenue share in the balloon valvuloplasty device market in 2022 and is projected to maintain its position over the forecast period. The increasing elderly population and the rising burden of valvular heart disease are factors driving the demand for surgical procedures in the U.S., further driving the market growth in the region.

• According to data published by the Centers for Disease Control & Prevention, around 2.5% of the population suffers from valvular heart disease in the U.S. The condition is highly prone to the elderly population.

Furthermore, the rising availability of medical reimbursements for balloon valvuloplasty devices, the growing adoption of minimally invasive surgeries, and the better healthcare infrastructure are additional factors influencing the market growth in the region.

Europe accounted for the second-highest market share in 2022. It is estimated to grow at a moderate CAGR during 2023-2030. The growth in the aged population is influencing the prevalence of valvular heart disease, which increases the chances of surgery, thereby boosting the regional market growth. Additionally, advancements in balloon valvuloplasty devices and favorable government initiatives focused on awareness generation about advanced surgical procedures are influencing market growth.

Asia Pacific is anticipated to grow at the fastest CAGR during the forecast period. The growth is mainly attributed to the thriving medical tourism industry in India, China, and Malaysia, which attracts heart patients from across the globe for treatment.

Furthermore, the Latin America and the Middle East & Africa markets are estimated to grow at a substantial CAGR from 2023-2030 due to the rising healthcare expenditure across Brazil, Mexico, and Argentina.

Key Players Covered

The report includes the profiles of key players such as Becton, Dickinson and Company, Balton, InterValve Medical Inc., B. Braun SE, TORAY INDUSTRIES, INC., pfm medical ag, Palex Medical SA, and others.

Key Industry Developments

• In December 2022, Abbott launched NavitorTM, a latest-generation TAVI (transcatheter aortic valve implantation) system to treat severe aortic stenosis in India who are at high or extreme surgical risk. The company is focused on advancing its surgical therapies with innovations to prevent blood from leaking around the valve.
• In September 2021, Abbott received the U.S. FDA approval for Portico with FlexNav transcatheter aortic valve replacement (TAVR). The system is used to treat patients with severe aortic stenosis who are at high risk for open-heart surgery.